In the first clinical trial evidence of its kind, semaglutide reduced multiple measures of epigenetic aging by up to 4.9 years and slowed the pace of aging by 9% compared to placebo in people with HIV-associated lipohypertrophy.
PhenoAge reduced by 4.9 yearsSemaglutide reversed nearly 5 years of biological aging as measured by the PhenoAge epigenetic clock over just 32 weeks of treatment — the first clinical trial evidence of a GLP-1 drug modulating aging biomarkers.
What the researchers found
In a post-hoc analysis of a 32-week, double-blind, placebo-controlled trial (semaglutide n=45, placebo n=39), semaglutide significantly decreased multiple epigenetic aging measures after adjustment for sex, BMI, hsCRP, and sCD163:
- PCGrimAge: -3.1 years (p=0.007)
- GrimAge V1: -1.4 years (p=0.02)
- GrimAge V2: -2.3 years (p=0.009)
- PhenoAge: -4.9 years (p=0.004)
- DunedinPACE: -0.09 units, approximately 9% slower pace of aging (p=0.01)
- OMICmAge: -2.2 years (p=0.009)
- RetroAge: -2.2 years (p=0.030)
Eleven organ-system clocks showed concordant decreases with semaglutide, most prominently in inflammation, brain, and heart clocks. An Intrinsic Capacity epigenetic clock was unchanged.
Why it matters
GLP-1 receptor agonists like semaglutide have been proposed as potential anti-aging drugs, but until now there was no clinical trial evidence supporting this. This study provides the first randomized, controlled evidence that semaglutide modulates validated epigenetic biomarkers of aging. If confirmed in broader populations, it could reframe GLP-1 drugs not just as diabetes/obesity treatments but as potential healthspan-extending therapies.
How the study worked
Post-hoc epigenetic analysis of a 32-week, double-blind, placebo-controlled Phase 2b clinical trial in adults with HIV-associated lipohypertrophy. Paired peripheral blood DNA methylation profiles were measured before and after treatment. Multiple generations of validated DNA methylation aging clocks were applied, and results were adjusted for sex, BMI, high-sensitivity CRP, and sCD163.
What this study cannot tell us
This was a post-hoc analysis, not a pre-specified endpoint of the original trial. The study population (people with HIV-associated lipohypertrophy) may have accelerated aging at baseline, so results may not generalize to healthy populations. The sample size was small (84 total). The trial was only 32 weeks, so durability of effects is unknown. Epigenetic clock changes are biomarker surrogates — it remains unproven whether they translate to actual healthspan extension. The study was published as a preprint (medRxiv) and has not yet been peer-reviewed.
How to read the evidence
This is a post-hoc analysis of a randomized, double-blind, placebo-controlled Phase 2b trial, which provides reasonably strong evidence. However, the post-hoc nature, small sample size, specific population, and preprint status (not yet peer-reviewed) limit the strength of conclusions. The consistent results across multiple validated clocks strengthen confidence.
When this study was published
Published as a 2025 preprint, this represents the cutting edge of research into GLP-1 receptor agonists and aging. Peer-reviewed publication is pending.
The bigger picture
The possibility that GLP-1 receptor agonists could slow biological aging is generating enormous interest. Epigenetic clocks are among the most validated biomarkers of aging, and seeing consistent reductions across multiple clock generations in a randomized trial is highly significant. If these epigenetic changes translate to actual health outcomes, GLP-1 drugs could become a cornerstone of longevity medicine — a massive expansion beyond their current metabolic disease indications.
Questions still open
- Will semaglutide show similar epigenetic aging effects in HIV-negative populations and healthy adults?
- Do these epigenetic clock changes translate to actual improvements in healthspan and reduced age-related disease?
- Are the anti-aging effects specific to semaglutide, or would other GLP-1 receptor agonists produce similar results?
Common questions
What are epigenetic clocks and what do they measure?
Does this mean semaglutide is an anti-aging drug?
Read the original research
Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.
medRxiv : the preprint server for health sciences
Citation
Corley, Michael J; Dwaraka, Varun; Pang, Alina Ps; Labbato, Danielle; Smith, Ryan; Eckard, Allison Ross; McComsey, Grace A. (2025). Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.. medRxiv : the preprint server for health sciences. https://doi.org/10.1101/2025.07.09.25331038